S Takahashi, M Colvin, J Toyosawa, M Ishida, T Kagawa, S Kuraoka, Y Aoyama, K Okamoto, I Sakakihara, K Izumikawa, K Yamamoto, S Tanaka, M Matsuura, S Ishikawa, M Wato, T Hasui, T Inaba, Journal of Crohn’s and Colitis, Volume 12, Issue supplement_1, February 2018

Cytapheresis therapy as an additional therapy to oral tacrolimus is effective in patients with severe ulcerative colitis.

)https://academic.oup.com/ecco-jcc/article/12/supplement_1/S328/4808317

Jia Huang, Qian Wang, Yongjing Cheng, Yingjuan Chen, Ming Gao, Feng Yang, Bingyao Mu, Rongwei Zhou, Cibo Huang, Altern Ther Health Med. 2020 Jul;26(4):36-42.

This study indicated that LCAP therapy can significantly decrease RA disease activity and is a safe and effective alternative therapy. LCAP therapy significantly reduced serum CXCL16 and serotonin levels, offering a putative mechanism by which it improves the articular symptoms of RA.

https://www.worldscientific.com/doi/10.1142/9789814749084_0031

Chiara De Cassan ¹, Edoardo Savarino ¹, Piero Marson ¹, Tiziana Tison ¹, Giorgia Hatem ¹, Giacomo Carlo Sturniolo ¹, Renata D’Incà ¹ , World J Gastroenterol. 2014 Dec 7;20(45):17155-62.

Patients with mild UC benefit from GMA more than patients with moderate to severe disease in the short-term period. GMA should be considered a valid therapeutic option in cases of contraindications to immunosuppressants, corticosteroids and/or biologics.

https://pubmed.ncbi.nlm.nih.gov/25493030/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258586/pdf/WJG-20-17155.pdf